Skip to main
LPCN
LPCN logo

Lipocine (LPCN) Stock Forecast & Price Target

Lipocine (LPCN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lipocine Inc. is focused on the development of innovative oral drug delivery solutions, with its leading product TLANDO poised for regulatory approval and commercialization in Canada, potentially boosting topline revenue. The promising clinical trial results of LPCN 1154, which may offer improved efficacy and safety over existing treatments for postpartum depression, highlight the company's strong pipeline and capacity to meet unmet medical needs. Additionally, a favorable market environment in Canada due to limited promotional activities for testosterone replacement therapies suggests Lipocine could capture a significant market share, further enhancing its growth prospects.

Bears say

Lipocine Inc reported a net loss of $3.2 million in the third quarter of 2025, highlighting ongoing financial challenges. The company faces several significant risks associated with its drug candidates, particularly LPCN 1154, which includes the potential for failure in clinical trials, lack of regulatory approval, and issues with market penetration and competition. Additionally, the risk of dilution further raises concerns regarding the company’s financial health and future performance.

Lipocine (LPCN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lipocine and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lipocine (LPCN) Forecast

Analysts have given Lipocine (LPCN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Lipocine (LPCN) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lipocine (LPCN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.